BJD Editor's Choice  by unknown
BJD EDITOR'S CHOICE
2558  © 2015 British Association of Dermatologists
from the British Journal of Dermatology
Mutational status of naevus-associated 
melanomas
This study explores the muta-
tional status of naevus-associat-
ed melanomas. The aim was to 
evaluate the presence of muta-
tions in genes from well-known 
melanomagenesis pathways 
in a large series of naevus- 
associated melanomas. Sixty-
one melanomas found in association with a pre-existing 
naevus were microdissected, after careful selection of cell 
subpopulations, and were submitted to Sanger sequencing of 
the BRAF, NRAS, KIT, PPP6C, STK19 and RAC1 genes. Each 
gene was evaluated twice in all samples by sequencing; by 
sequencing and another confirmation method, allele-specific 
fluorescent polymerase chain reaction and capillary electro-
phoresis detection; or by SNaPshot analysis. Only mutations 
confirmed via two different molecular methods or twice by 
sequencing were considered positive. The majority of cases 
studied presented concordance of mutational status between 
melanoma and the associated naevus for all six genes (40 
of 60; 67%). Nine cases presented concomitant BRAF and 
NRAS mutations, including one case in which both the mela-
noma and the adjacent naevus harboured V600E and Q61K 
double mutations. In two cases, both the melanoma and the 
associated naevus located on acral sites were BRAF mutated, 
including an acral lentiginous melanoma. The authors claim 
this to be the largest naevus-associated melanoma series 
evaluated molecularly. They report that the majority of mela-
nomas and adjacent naevi studied shared the same mutation-
al profile, corroborating the theory that the adjacent naevus 
and melanoma are clonally related and that the melanoma 
originated within a naevus. Br J Dermatol 2015; 173: 671-
680: 10.1111/bjd.13829
A prospective qualitative study on 
discharge decision making
This study concerns outpatient discharge decision-making 
in dermatology. The authors aimed to identify the influenc-
es on clinicians’ thought processes when making discharge 
decisions in dermatology outpatients. To do this they inter-
viewed 40 clinicians from 11 National Health Service trusts 
in England. The interviews were audio recorded, transcribed, 
coded and thematically analysed. The clinicians’ mean age 
was 48.8 years (range 33–67), 17 (43%) were male and 19 
(48%) had >20 years’ clinical experience. Overall 148 influ-
ences were reported, with five main themes. Disease-based 
influences included the type of diagnosis (mentioned by 
100% of clinicians), guidelines (100%), and treatment need-
ed (100%). Clinician-based influences were the clinician’s 
level of experience (100%), seniority (38%), emotional atti-
tude (95%), ‘gut feeling’ (25%), personal attitude towards dis-
charge (45%) and level of perception (100%). Patient-based 
influences included patients’ ability to cope with their dis-
ease (100%), wishes (70%), quality of life (32%), command 
of English (40%) and cultural background (25%). Practice-
based influences included good primary care (100%), sec-
ondary support structure (100%), and clinic capacity pres-
sure (68%). Policy-based influences included pressure from 
hospital managers (58%) and an active discharge policy 
(8%). Fourteen influences (9%) were potentially inappropri-
ate. The authors of this study report multiple factors that influ-
ence outpatient discharge decision making. They conclude 
that this now provides the basis to develop evidence-based 
training to improve discharge decision appropriateness. Br J 
Dermatol 2015; 173: 720-730: doi: 10.1111/bjd.13946
Rapid, reliable, cost-effective molecular 
diagnosis of epidermolysis bullosa
The extreme clinical and genetic heterogeneity of epider-
molysis bullosa (EB) means that labour-intensive and expen-
sive tests are required to establish the correct diagnosis. The 
investigators aimed to develop a customized, cost-efective 
amplicon panel for the complete and accurate sequencing of 
all the pathogenic genes already identified in EB. Additionally, 
they aimed to minimize the processing time required for the 
execution of the test and to refine the analytical pipeline to 
achieve cost-effective results from the perspective of a rou-
tine laboratory set-up. The investigators used next-generation 
sequencing (NGS) via the parallel ultradeep sequencing of 
many genes as a method for reducing the processing time 
and costs of EB diagnostics. A panel of EB disease-compre-
hensive genes in AmpliSeq was established for NGS on an 
Ion Torrent Personal Genome Machine platform. The panel 
was performed on 10 patients with known genetic diagnoses 
and was then employed in eight family trios with unknown 
molecular footprints. The panel was successful in finding the 
causative mutations in all 10 patients with known mutations, 
fully confirming the Sanger sequencing data and providing 
proof of concept of the sensitivity, specificity and accuracy of 
this procedure. In addition to the panel being consistent with 
the clinical diagnosis, they reported that it was also effec-
tive in the trios, identifying all of the variants, including ones 
that the Sanger sequencing missed or de novo mutations. The 
authors concluded that NGS and AmpliSeq made an effective 
approach for the diagnosis of EB, resulting in a cost- and time-
effective 72-h procedure. Br J Dermatol 2015; 173: 731-738: 
doi: 10.1111/bjd.13858
